These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23268284)

  • 1. Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats.
    Sugiyama F; Kobayashi N; Ishikawa M; Onoda S; Ishimitsu T
    Clin Exp Nephrol; 2013 Aug; 17(4):515-24. PubMed ID: 23268284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal amounts of intracellular calcium regulatory proteins in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome and cardiac dysfunction.
    Kagota S; Maruyama K; Tada Y; Wakuda H; Nakamura K; Kunitomo M; Shinozuka K
    Can J Physiol Pharmacol; 2013 Feb; 91(2):124-33. PubMed ID: 23458196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure.
    Ishikawa M; Kobayashi N; Sugiyama F; Onoda S; Ishimitsu T
    Int Heart J; 2013; 54(2):98-106. PubMed ID: 23676370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
    Kagota S; Tada Y; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
    Can J Physiol Pharmacol; 2011 May; 89(5):355-64. PubMed ID: 21619437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats.
    Obata J; Nakamura T; Takano H; Naito A; Kimura H; Yoshida Y; Shimizu F; Guo DF; Inagami T
    J Hypertens; 2000 Sep; 18(9):1247-55. PubMed ID: 10994756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular remodeling and metabolic abnormalities in SHRSP.Z-Lepr(fa)/IzmDmcr rats as a new model of metabolic syndrome.
    Ueno T; Takagi H; Fukuda N; Takahashi A; Yao EH; Mitsumata M; Hiraoka-Yamamoto J; Ikeda K; Matsumoto K; Yamori Y
    Hypertens Res; 2008 May; 31(5):1021-31. PubMed ID: 18712058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.
    Kagota S; Maruyama K; Wakuda H; McGuire JJ; Yoshikawa N; Nakamura K; Shinozuka K
    Vascul Pharmacol; 2014 Oct; 63(1):46-54. PubMed ID: 25109437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
    Nishiyama A; Nakagawa T; Kobori H; Nagai Y; Okada N; Konishi Y; Morikawa T; Okumura M; Meda I; Kiyomoto H; Hosomi N; Mori T; Ito S; Imanishi M
    J Hypertens; 2008 Sep; 26(9):1849-59. PubMed ID: 18698221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poricoic acid ZA, a novel RAS inhibitor, attenuates tubulo-interstitial fibrosis and podocyte injury by inhibiting TGF-β/Smad signaling pathway.
    Wang M; Chen DQ; Wang MC; Chen H; Chen L; Liu D; Zhao H; Zhao YY
    Phytomedicine; 2017 Dec; 36():243-253. PubMed ID: 29157821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive therapy with statins reduces residual albuminuria/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy.
    Zhang Z; Li Z; Cao K; Fang D; Wang F; Bi G; Yang J; He Y; Wu J; Wei Y; Song X
    J Hypertens; 2017 Jul; 35(7):1442-1456. PubMed ID: 28244896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.
    Nishiyama A; Kobori H; Konishi Y; Morikawa T; Maeda I; Okumura M; Kishida M; Hamada M; Nagai Y; Nakagawa T; Ohashi N; Nakano D; Hitomi H; Imanishi M
    J Pharmacol Exp Ther; 2010 Mar; 332(3):1072-80. PubMed ID: 19940106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of cardiac size and function in SHRSP.Z-Lepr(fa)/IzmDmcr rats, a new animal model of metabolic syndrome.
    Tada Y; Kagota S; Matsumoto M; Naito Y; Shibata H; Nejime N; Tsujino T; Koshiba M; Masuyama T; Shinozuka K
    Biol Pharm Bull; 2010; 33(12):1971-6. PubMed ID: 21139235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan counteracts TGF-β1 induced epithelial-to-mesenchymal transition via PPAR-γ in human proximal tubule epithelial cells.
    Chen Y; Luo Q; Xiong Z; Liang W; Chen L; Xiong Z
    Int J Clin Exp Pathol; 2012; 5(6):522-9. PubMed ID: 22949934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
    Khan AH; Imig JD
    Am J Hypertens; 2011 Jul; 24(7):816-21. PubMed ID: 21415842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
    Fan YY; Kohno M; Nakano D; Ohsaki H; Kobori H; Suwarni D; Ohashi N; Hitomi H; Asanuma K; Noma T; Tomino Y; Fujita T; Nishiyama A
    J Hypertens; 2010 May; 28(5):1034-43. PubMed ID: 20411599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of TRPC6 Signal Pathway Alleviates Podocyte Injury Induced by TGF-β1.
    Huang H; You Y; Lin X; Tang C; Gu X; Huang M; Qin Y; Tan J; Huang F
    Cell Physiol Biochem; 2017; 41(1):163-172. PubMed ID: 28214865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effects of telmisartan in the 5/6 nephrectomised rats.
    Tsunenari I; Ohmura T; Seidler R; Chachin M; Hayashi T; Konomi A; Matsumaru T; Sumida T; Hayashi N; Horie Y
    J Renin Angiotensin Aldosterone Syst; 2007 Jun; 8(2):93-100. PubMed ID: 17703436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
    Villa L; Boor P; Konieczny A; Kunter U; van Roeyen CR; Denecke B; Gan L; Neusser MA; Cohen CD; ; Eitner F; Scholl T; Ostendorf T; Floege J
    J Pathol; 2013 Apr; 229(5):672-84. PubMed ID: 23192593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.
    Watanabe D; Tanabe A; Naruse M; Morikawa S; Ezaki T; Takano K
    Hypertens Res; 2009 Sep; 32(9):807-15. PubMed ID: 19662019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.